Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib 2% Cream in Early-Stage Cutaneous T-cell Lymphoma
NCT06698822Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INN-04-01 in cutaneous T-cell lymphoma (CTCL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2025; status: recruiting.
02
Drugs
INN-04-01
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT06698822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698822.